If you or your doctor feels a lump in your breast or an area of concern shows up on a mammogram, the next step may be breast ultrasound to help decide if the mass is cancer and whether it should be biopsied. Most lumps or areas of concern turn out to be benign (not cancer).
The two studies reviewed here strongly suggest that breast ultrasound is very good at distinguishing between benign lumps (called lesions in the studies) and cancer in women younger than 40. So breast ultrasound may be able to help women younger than 40 avoid unnecessary biopsies.
In the first study, the researchers wanted to know if monitoring breast lumps with ultrasound was as accurate as doing a biopsy. So they looked at 1,091 lumps in 830 women younger than 30 with one or more ultrasounds. Based on the ultrasound results, the lumps were classified as benign, moderate-risk, or high-risk. The high-risk lumps were biopsied. All the women were followed for 2 years.
In the second study, 1,327 lumps in 1,032 women aged 30 to 39 were evaluated with an ultrasound and followed over time. Biopsies were done if the ultrasound suggested the lump could be cancer.
These studies strongly suggest that breast ultrasound is very good at distinguishing between benign lumps and cancer in women younger than 40. So lumps classified as benign or moderate risk likely can be carefully monitored without a biopsy. Other studies have shown that ultrasound can be effectively used the same way in women older than 40.
If you or your doctor finds a breast lump or a mammogram shows a mass or suspicious area, you'll understandably worry that you may have cancer. Be reassured that the odds are in your favor that the lump or mass isn't cancer. If you've found a breast lump, you may think an immediate biopsy to get an immediate answer is the best choice. Still, remember that a biopsy is an invasive procedure that should be done only when absolutely necessary.
Research suggests that ultrasound can be a very good alternative to immediate biopsy, allowing some women to avoid an unnecessary biopsy. If your doctor recommends a wait-and-watch approach with ultrasound surveillance but that approach doesn't feel right to you, talk to your doctor about your situation, your concerns, and your preferences. Together you can decide on a plan that makes the most sense for you.
CHICAGO (MedPage Today) -- Using ultrasound to examine lumps and suspicious areas of the breast may be an effective alternative to biopsy for women under 40, researchers said here.
In two analyses, targeted ultrasound correctly distinguished between cancerous and benign lesions in the majority of cases, Constance Lehman, MD, of the University of Washington, and colleagues reported at the Radiological Society of North America meeting here.
"Ultrasound is a valuable tool in evaluating focal signs in women under 40," Lehman said. "The high sensitivity supports use of ultrasound over surgical excision."
She said that a targeted ultrasound is typically performed for women under 40 with palpable masses. However, little data exists on outcomes, and there are lingering questions about the need for concurrent mammography and the safety of ultrasound surveillance compared with biopsy.
So to determine imaging accuracy and malignancy outcomes, the researchers conducted a retrospective review of all breast ultrasound examinations performed at their facility between 2002 and 2006 in two separate studies.
In the first study, the researchers evaluated the accuracy of ultrasound as a primary diagnostic modality in women younger than 30 who had breast lumps. They also evaluated whether ultrasound surveillance had advantages over tissue sampling.
"We wanted to know, is it safe to follow a patient with ultrasound rather than perform surgery?" Lehman said.
Patients received either 24 months of imaging surveillance or biopsy.
A total of 1,091 lesions were examined in 830 women.
The researchers found that in two-thirds of patients, the lesions were identified as benign using ultrasound, and none were cancerous -- a 100% sensitivity.
A total of 17% of patients were classified as moderate risk for cancer via the ultrasound and were recommended for ultrasound surveillance. The remaining 20% were classified as high-risk, and were referred for biopsy.
Lehman said there were only three cases of cancer in the 164 women who had been referred for biopsy.
The test's specificity, she said, was 79.3%.
She added that 33% of those who were recommended for close surveillance wound up having a biopsy, most often because they requested it. None of their lesions were malignant.
"Patients often want tissue sampling anyway," Lehman said. "But if we have confidence in our imaging tools, we can give women more security that they can be surveilled [with imaging] rather than having an intervention."
For the second study, the researchers looked at data on women ages 30 to 39, evaluating 1,327 palpable masses in 1,032 patients.
In this age group, they found that 98% of examined lumps were benign, which is "reassuring for women," but still calls attention to the 2% malignancy rate in this young age group, Lehman said.
Again, all masses were correctly detected by ultrasound, making for a 100% sensitivity, but the specificity of the diagnostic test was still lower at 89%.
Lehman noted that its specificity precludes ultrasound from being a useful screening tool.
"Ultrasound is a fantastic tool in the diagnostic setting," she said. "But we have not found it to have the performance we need to use it as a screening tool."
The findings are "timely with the U.S. Preventive Services Task Force (USPSTF) recommendations that women don't perform self-examinations," Lehman said. "Women will identify certain areas" that are potentially cancerous via such exams.
Fewer than 2% of women under 40 who present with palpable masses or localized pain actually have cancer, she said, but this figure is not something to which to turn a blind eye.
"Dr. Lehman's study shows that we can be comfortable in starting out diagnostic workup with ultrasound in these women," said Joseph Tashjian, MD, of St. Paul Radiology in St. Paul, Minn. "We have had the same experience as Dr. Lehman with ultrasound. We find it very reliably answers the question as to whether the lesion is cancer or normal breast tissue."
Two co-authors reported a relationship with General Electric Company, and one with Johnson & Johnson.
Primary source: Radiological Society of North America Source reference: Lehman C, et al "Outcomes of targeted ultrasound evaluation in women under 30 years of age with focal breast signs or symptoms" RSNA 2009; Abstract SSK02-08.
Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003
Learn more about our commitment to your privacy
© 2010 Breastcancer.org - All rights reserved.
Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.
